Scinai Immunotherapeutics (SCNI) Debt to Equity (2018 - 2025)

Scinai Immunotherapeutics has disclosed Debt to Equity across 8 years of filings, most recently posting $0.1 for Q4 2025.

• Debt to Equity for Q4 2025 came in at $0.1, up 46.89% year-over-year; the trailing twelve-month figure through Dec 2025 was $0.1 (up 46.89% YoY), and the FY2025 annual result was $0.1, up 46.89% from the prior year.
• Debt to Equity came in at $0.1 for Q4 2025 at Scinai Immunotherapeutics, up from $0.07 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $28.04 in Q4 2021 to a low of -$25.85 in Q1 2022.
• The 5-year median for Debt to Equity is $0.02 (2022), against an average of -$0.14.
• Across the five-year window, Debt to Equity surged 147.27% in 2021 and slumped 141.46% in 2022, its largest moves.
• Scinai Immunotherapeutics' Debt to Equity stood at $28.04 in 2021, then plunged by 141.46% to -$11.63 in 2022, then surged by 62.8% to -$4.33 in 2023, then soared by 101.58% to $0.07 in 2024, then surged by 46.89% to $0.1 in 2025.
• The last three Debt to Equity figures came in at $0.1 (Q4 2025), $0.07 (Q4 2024), and -$4.33 (Q4 2023), per Business Quant data.